Dr. Raj B. Parekh is an Independent Director at Eloxx Pharmaceuticals, Inc., a General Partner at Advent Life Sciences LLP, a Chairman at Galapagos NV and a Professor at University of Oxford. He is on the Board of Directors at Eloxx Pharmaceuticals, Inc., Arrakis Therapeutics, Inc., Capella Bioscience Ltd., Advent LS Services Ltd., Aleta Biotherapeutics, Inc., Aleta, Inc., Alpha Anomeric SA, Alpha Anomeric SAS, Amphista Therapeutics Ltd., Arrakis, Inc., Artax, Inc., Aura Biosciences, Inc., Aura, Inc., Cellnovo Ltd., Itara Ltd., Levicept Ltd., Performance Electronics Ltd., Project Paradise Ltd., Rappta Therapeutics Oy, Tridek-One Therapeutics SAS, Zikani Therapeutics, Inc., Novartis Venture Fund and Biocartis SA. Dr. Parekh was previously employed as a General Partner by Advent Venture Partners LLP, a Non-Executive Chairman by Chroma Therapeutics Ltd., a CEO, Chief Scientific Officer & Senior VP-Research by Oxford GlycoSciences Plc, a Director-Supervisory Board by 4-Antibody AG, a Non-Executive Director by Biocartis Group NV, a Chief Executive Officer & Director by Biocartis SA, a Chairman by CoCo Therapeutics Ltd., a Non-Executive Director by EUSA Pharma, Inc., a Non-Executive Director by F2G Ltd., and a Non-Executive Director by Jazz Pharmaceuticals UK Ltd. He also served on the board at Cellnovo Group SA, AVANT Immunotherapeutics, Inc., Celldex Therapeutics, Inc., Celldex Research Corp., Amsterdam Molecular Therapeutics (AMT) Holding NV, Artax Biopharma, Inc., Avant! Corp. (California), Avila Therapeutics, Inc., Biocartis NV, Luxfold S.A., NeRRe Therapeutics Ltd. and Thiakis Ltd. He received his undergraduate degree from the University of Oxford, a graduate degree from the University of Oxford and a doctorate degree from the University of Oxford.